Median survival from 5-azacytidine was 108 days, 21 patients proceeded to subsequent transplant. In multivariate analysis, peripheral blood blasts <1% were predictive of longer OS (P=0.03).

Patients received 5-azacytidine s.c., at a total daily dose of 100 mg, on days 1–3, to be followed by DLI on day 10, with the next course of treatment to be started on day 22.

PURPOSEIn contrast to 5-azacytidine (5-aza), allogeneic stem-cell transplantation (HSCT) represents a curative treatment strategy for patients with myelodysplastic syndromes (MDS), but therapy-related ...

Although hypomethylating agents (HMAs) such as 5-azacytidine (AZA) are the standard of care in myelodysplastic syndromes (MDS), most patients do not experience durable remissions and will ...

The scientists show that the gene can be reactivated by treatment with an existing drug, 5-azacytidine. The results suggest that 5-azacytidine may function as targeted therapy for ALL in children.

Patients received ruxolitinib twice daily in 28-day cycles for the first three cycles and azacytidine 25 mg/m 2 on days 1 through 5 starting in cycle 4. Azacytidine dosing could be increased to 75 ...

Combination of TAK-981 and 5-azacytidine shows efficacy in acute myeloid leukemia models Jan. 17, 2024 SUMOylation is a post-translational modification implicated in DNA damage repair that has been ...

Researchers have suggested that the existing drug 5-azacytidine may offer hope as a new therapy for treating acute lymphoblastic leukaemia (ALL) in children. Results from a new study, completed at ...

A recent study discovered that applying 5-Azacytidine, a DNA methylation inhibitor, significantly reduces tomato susceptibility to gray mold, a common postharvest fungal disease.

The standard dosing schedule for hypomethylating agents, such as azacytidine, is 7 days, but some patients are given a 5-day dosing schedule, with little evidence to guide these decisions.